July/August 2016

 

Issue

Insert

Supplement

UP FRONT

Adapting to Change

By Steven D. Vold, MD

THE LITERATURE

The Literature

By Leonard K. Seibold, MD; Malik Y. Kahook, MD; and Jeffrey R. SooHoo, MD

BENCH TO BEDSIDE

What Is the Real IOP?

Laboratory studies may help us better understand our clinical dilemmas.

By Dan Eisenberg, MD

RESEARCH RESULTS

Highlights of the 2016 ARVO Annual Meeting

Select research findings presented this year.

By Sze H. Wong, MD, and Albert S. Khouri, MD

CHALLENGING CASES

Glaucoma After Corneal Limbal Stem Cell Transplantation

By Ahmad A. Aref, MD; Kavitha R. Sivaramen, MD; and Ali R. Djalilian, MD

RESIDENTS AND FELLOWS

Foundations of a Great Physician

By Linda Huang, MD

COVER FOCUS: Ocular Surface Disease

Ocular Surface Disease: Impact on Glaucoma Surgical Decision Making

The preoperative planning process is more complex and requires careful attention to the unique issues at play.

By Tony Realini, MD, MPH

The Dark Side of Medication

Many systemic and topical drugs can cause or worsen dry eye disease.

By Sarah Marshall, PhD, and Robert Noecker, MD, MBA

Tear Osmolarity in a Glaucoma Practice

The role of point-of-care testing in dry eye disease and glaucoma management.

By Leslie E. O’Dell, OD

Corneal Imaging

The principles and clinical significance of various technologies.

By Alice T. Epitropoulos, MD

Intense Pulsed Light for Dry Eye Disease

This procedure improves the health of the meibomian glands.

By Rolando Toyos, MD

What Every Glaucoma Doctor Should Know About DED

New technologies provide more information and better outcomes than ever before.

By Sheri Rowen, MD

Punctal Occlusion and Ocular Nutrition

By Paul S. Koch, MD, and Thandeka Myeni, MD, MPH

Neurostimulation: a Novel Approach to Treating the Signs and Symptoms of Dry Eye

A device in clinical study could lead to new understanding of dry eye as a neuronal disease.

By John Berdahl, MD

PRACTICE POINTERS

Being a Doctor, Thinking Like a CEO

The merging of two mindsets requires skill, versatility, and sensitivity.

By Wolfgang Riha, MD

IN BACK

Industry News

News Feature: a New Option for Uveitis

Adalimumab, a rheumatology drug, offers hope to patients with this damaging inflammatory eye disease.

By Agustin L. Gonzalez, OD

INSIDE EYETUBE.NET

Closure to a Long-Standing Ordeal With a Cleft

By Jonathan S. Myers, MD
 

Contact Info

Bryn Mawr Communications LLC
1008 Upper Gulph Road, Suite 200
Wayne, PA 19087

Phone: 484-581-1800
Fax: 484-581-1818

About Glaucoma Today

Glaucoma Today is mailed bimonthly (six times a year) to 11,519 glaucoma specialists, general ophthalmologists, and clinical optometrists who treat patients with glaucoma. Glaucoma Today delivers important information on recent research, surgical techniques, clinical strategies, and technology.